Switch theme
Sign up to access all valuation multiples
Brightgene Bio-medical Technology Co Ltd is a pharmaceutical company engaged in research, development and production of new drugs and high-end generic drugs. The company develops macrolides, peptides, polysaccharides, heterocycles, azoles, azines, phenyl ethers, tetracyclines, and production of non-pharmaceutical macrolides, peptides, polysaccharides, heterocycles, azoles, azines, benzene Ethers, tetracyclines.
2001
n/a
LTM Revenue $180M
LTM EBITDA $58.3M
$3.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Brightgene Bio-medical has a last 12-month revenue (LTM) of $180M and a last 12-month EBITDA of $58.3M.
In the most recent fiscal year, Brightgene Bio-medical achieved revenue of $179M and an EBITDA of $44.8M.
Brightgene Bio-medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Brightgene Bio-medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $180M | XXX | $179M | XXX | XXX | XXX |
| Gross Profit | $108M | XXX | $103M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $58.3M | XXX | $44.8M | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $30.4M | XXX | $35.0M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $31.3M | XXX | $26.4M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $128M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Brightgene Bio-medical's stock price is CNY 54 (or $8).
Brightgene Bio-medical has current market cap of CNY 22.9B (or $3.2B), and EV of CNY 24.3B (or $3.4B).
See Brightgene Bio-medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.4B | $3.2B | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Brightgene Bio-medical has market cap of $3.2B and EV of $3.4B.
Brightgene Bio-medical's trades at 19.0x EV/Revenue multiple, and 75.8x EV/EBITDA.
Equity research analysts estimate Brightgene Bio-medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Brightgene Bio-medical has a P/E ratio of 102.0x.
See valuation multiples for Brightgene Bio-medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV/Revenue | 18.9x | XXX | 19.0x | XXX | XXX | XXX |
| EV/EBITDA | 58.2x | XXX | 75.8x | XXX | XXX | XXX |
| EV/EBIT | 111.5x | XXX | 97.0x | XXX | XXX | XXX |
| EV/Gross Profit | 31.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 102.0x | XXX | 121.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2090.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBrightgene Bio-medical's last 12 month revenue growth is 8%
Brightgene Bio-medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Brightgene Bio-medical's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Brightgene Bio-medical's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Brightgene Bio-medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 26% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Brightgene Bio-medical acquired XXX companies to date.
Last acquisition by Brightgene Bio-medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Brightgene Bio-medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Brightgene Bio-medical founded? | Brightgene Bio-medical was founded in 2001. |
| Where is Brightgene Bio-medical headquartered? | Brightgene Bio-medical is headquartered in China. |
| Is Brightgene Bio-medical publicy listed? | Yes, Brightgene Bio-medical is a public company listed on SHG. |
| What is the stock symbol of Brightgene Bio-medical? | Brightgene Bio-medical trades under 688166 ticker. |
| When did Brightgene Bio-medical go public? | Brightgene Bio-medical went public in 2019. |
| Who are competitors of Brightgene Bio-medical? | Similar companies to Brightgene Bio-medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Brightgene Bio-medical? | Brightgene Bio-medical's current market cap is $3.2B |
| What is the current revenue of Brightgene Bio-medical? | Brightgene Bio-medical's last 12 months revenue is $180M. |
| What is the current revenue growth of Brightgene Bio-medical? | Brightgene Bio-medical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Brightgene Bio-medical? | Current revenue multiple of Brightgene Bio-medical is 18.9x. |
| Is Brightgene Bio-medical profitable? | Yes, Brightgene Bio-medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Brightgene Bio-medical? | Brightgene Bio-medical's last 12 months EBITDA is $58.3M. |
| What is Brightgene Bio-medical's EBITDA margin? | Brightgene Bio-medical's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Brightgene Bio-medical? | Current EBITDA multiple of Brightgene Bio-medical is 58.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
